Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM
1. Actinium Pharmaceuticals faces a class action securities lawsuit over alleged fraud.
2. The suit claims misleading statements about the Iomab-B BLA application process.
3. Concerns raised about Phase 3 Sierra trial data meeting FDA requirements.
4. Investors can join the lawsuit for potential compensation without upfront costs.
5. Plaintiffs must act by May 27, 2025, to be considered for lead plaintiff.
The lawsuit indicates serious potential compliance and approval issues with Iomab-B, likely unsettling investors. Previous cases, such as with Novavax, show how legal troubles can drastically impact stock prices.
How important is it?
The article addresses significant legal issues that could derail investor confidence and jeopardize Iomab-B's approval, thus fostering a potentially devastating short-term market reaction.
Why Short Term?
Pending litigation outcomes will likely affect ATNM's stock in the coming months. Historically, investors react quickly to news involving lawsuits.
Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit.
CLASS DEFINITION:
The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team:
ATNM investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
CASE DETAILS:
The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company's data from the Phase 3 Sierra trial was unlikely to satisfy the FDA's guidelines for the acceptance and approval of the Company's targeted radiotherapy, Iomab-B BLA; (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate the Sierra Trial's poor OS data were unlikely to satisfy the FDA's guidelines for the acceptance and approval of the Company's Iomab-B BLA; (3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and (4) as a result, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
WHAT'S NEXT?
If you suffered a loss in Actinium during the relevant time frame, you have until May 27, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU:
If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY:
Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004 [email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171 www.zlk.com
